Clinical Trial Update: Evaluation of the Efficacy and Safety of Nano-S1 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of Nano-S1 for COVID-19 pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Nano-S1

Snippet

Sponsor: General Administration of Military Health, Tunisia | Conditions: COVID-19 Pneumonia | Phase 3 | Status: COMPLETED